Welcome!!

FDA Shares is Latest Thinking on Oncology Trial Eligibility
The series of draft guidances encourages a broadening of eligibility criteria.
Scotland Turns Down Kymriah Over Cost-Effectiveness
Evidence “not strong enough” to justify expense, regulator says.
Oklahoma AG Seeks J&J Docs in Opioid Lawsuit
J&J labeled “kingpin” of opioid crisis.
FDA Green Lights New Generic Valsartan
Agency prioritized review to stave off shortages.
NCI Director Sharpless Named Acting FDA Director
Sharpless has advocated for increased modernization of clinical trials.

AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
GW sells priority review voucher for $105m
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
Setback for Allergy’s birch pollen immunotherapy
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
Groundbreaking study finds optimum dosage of IV iron for kidney patients
New iron-trial results have paved the way for improved haemodialysis treatment.
Lewy Body Society grants £1 million for dementia research
The Lewy Body Society has announced that the latest recipients of its grant programme will be University of Cambridge, Newcastle University and Imperial College London.
Molecular patterns could better predict breast cancer recurrence
A study has found that molecular patterns could better predict breast cancer recurrence.